Having had a week to mull over the FDA's latest batch of social media guidance, some observers have concluded the agency is making a blunt statement to brand managers: Don't use Twitter.
Any brand managers eager to jump into Twitter as soon as the FDA gave the go-ahead? No such luck. Last week's social media guidance on risk disclosures may have cleared up some of the regulatory fog, but in this case, clarity isn't a positive.
The FDA continued to build its patchwork quilt of social media guidance this week with the publication of two new draft documents, one of which is the long-awaited discussion on how to use Twitter. And while the guidance places significant constraints on how biopharma can use the platform, some think the clarity it brings will prompt companies to become more active tweeters.
Authorities removed more than 19,000 ads on Facebook, Twitter and YouTube that promoted the illegal sale of medicines.
The steady flow of posts about adverse events on social media provide an interesting opportunity for the FDA to improve postmarketing safety surveillance. Yet an FDA-funded study has found that mining the data for insights is difficult, with humans still better equipped than machines to decipher chatter on Twitter.
Sanofi has added a new Twitter handle to its Iberian lineup, @Sanofifarmacia, designed to create a pool of reference information and help community pharmacies in Spain promote their businesses.
Which pharma companies are getting it right when it comes to social media? As far as Twitter is concerned, Boehringer Ingelheim is up there.
Biopharma has encountered more critics than cheerleaders as it has cautiously edged into social media, but Boehringer Ingelheim has recently won a high-profile supporter: Twitter. In a case study, the social network praised Boehringer's use of its platform.
Chatting with the public is not in pharma's comfort zone. Drugmakers are adept at the one-way communication known as direct-to-consumer advertising, and some of them deal well with the media....
Forget a unified theory of social media from the FDA. It's going to be more of a puzzle-piece approach. As Regulatory Focus reports, the FDA plans to issue several more sets of rules for pharma companies using Twitter, Facebook, Pinterest, et al.